Whether they ever will depends less on the receptor, whose biology is no longer in serious doubt, than on two engineering problems that the recent failures have brought into focus: getting the compound to the right neurons, and getting the right patients into the trial
The two medications work through entirely different pharmacological pathwaysescitalopram affects central serotonin neurotransmission, whilst semaglutide acts primarily on GLP-1 receptors in the gut and brain
Hoffman, J
How GLP-1 drugs reduce cravings in people with addiction is not well understood, but the authors of the new paper offer one possibility
Discussion Our findings elucidate an intricate relationship between abnormal serum lipids, particularly palmitoyl-L-carnitine, and neurodegenerative processes, highlighting a potential mechanism through which lipid dysregulation exacerbates conditions like AD
However, many gastrointestinal issues may be resolved once the medication is stopped or the dosage is lowered